The PI3K inhibitor copanlisib has demonstrated significant efficacy and a manageable safety profile in patients with relapsed/refractory gastric MALT lymphoma who have received intensive treatment, and may be a salvage treatment option for patients [71]. This evidence concerns the gene PIK3CD and MALT lymphoma.